Head-to-head evidence
Aripiprazole lauroxil (Aristada Initio) vs Brexpiprazole (Rexulti)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline
Aripiprazole lauroxil (Aristada Initio)
Marketed by Alkermes plc
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Brexpiprazole (Rexulti)
Marketed by Otsuka Holdings and partners
NCT01393613 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 674 patients with acute schizophrenia, using a validated symptom-severity scale (PANSS) as the primary measure. The pooled comparison of the two higher doses against placebo reached statistical significance (p=0.0093), and the 4 mg dose was significant on its own, but the 1 mg and 2 mg doses individually did not separate from placebo, so the result was only partially met.
Next expected readout: August 2027 · NCT07742280 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole lauroxil (Aristada Initio)'s landscape · Brexpiprazole (Rexulti)'s landscape